Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder. (Q48099646)

8 February 2018

title

Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder. (English)

1 reference

8 February 2018

post-traumatic stress disorder

main subject

tetrahydrocannabinol

0 references

cannabinoids

0 references

1 reference

2

Raphael Mechoulam

1 reference

8 February 2018

Pablo Roitman

1

1 reference

8 February 2018

Rena Cooper-Kazaz

series ordinal

3

1 reference

8 February 2018

Arieh Shalev

series ordinal

4

1 reference

8 February 2018

publication date

1 August 2014

1 reference

8 February 2018

Clinical Drug Investigation

published in

1 reference

8 February 2018

volume

34

1 reference

8 February 2018

page(s)

587-591

1 reference

8 February 2018

issue

8

1 reference

8 February 2018

Cannabis use among military veterans after residential treatment for posttraumatic stress disorder

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40261-014-0212-3

The endocannabinoid system as an emerging target of pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-014-0212-3

Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-014-0212-3

Cannabis and anxiety: a critical review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-014-0212-3

Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-014-0212-3

The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-014-0212-3

PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-014-0212-3

The endogenous cannabinoid system controls extinction of aversive memories

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-014-0212-3

Cannabinoid facilitation of fear extinction memory recall in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-014-0212-3

The development of a Clinician-Administered PTSD Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-014-0212-3

The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-014-0212-3

Nightmare frequency in sexual assault survivors with PTSD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-014-0212-3

A controlled study of imagery rehearsal for chronic nightmares in sexual assault survivors with PTSD: a preliminary report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-014-0212-3

Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-014-0212-3

Open-label, add-on study of tetrahydrocannabinol for chronic nonmalignant pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-014-0212-3

Using cannabis to help you sleep: heightened frequency of medical cannabis use among those with PTSD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-014-0212-3

Effect of illicit recreational drugs upon sleep: cocaine, ecstasy and marijuana

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-014-0212-3

PTSD and traumatic stress from gene to community and bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-014-0212-3

Endocannabinoid system dysfunction in mood and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-014-0212-3

Chronic PTSD in Vietnam combat veterans: course of illness and substance abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-014-0212-3

Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study

21 January 2018

1 reference

12 December 2020

Psychosis associated with medical marijuana: risk vs. benefits of medicinal cannabis use

1 reference

12 December 2020

Pharmacotherapy of posttraumatic stress disorder: a review of meta-analyses and treatment guidelines.

1 reference

12 December 2020

The therapeutic potential of cannabis and cannabinoids

1 reference

12 December 2020

10.1007/S40261-014-0212-3

Identifiers

DOI

1 reference

8 February 2018

PubMed ID

24935052

1 reference

8 February 2018